Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORNADO neoadjuvant retifanlimab plus doxorubicin/ifosfamide in resectable undifferentiated pleomorphic sarcoma
2023-509498-21-00Phase 2Authorised
- Sponsor
- Institut Bergonié
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of retifanlimab in Malignant Fibrous Histiocytoma (MFH), retroperitoneal sarcoma (RPS) and soft tissue sarcoma (STS) (2 arms), sponsored by Institut Bergonié. Primary endpoint: Histological response. Planned start Mar 2022; status: authorised.
02
Drugs
retifanlimab
03
Conditions
Malignant Fibrous Histiocytoma (MFH)retroperitoneal sarcoma (RPS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2023-509498-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509498-21-00.